We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





DCN Diagnostics and Asahi Kasei Fibers Launch Market Collaboration

By LabMedica International staff writers
Posted on 30 Jul 2013
Print article
DCN Diagnostics (Carlsbad, CA, USA) and Asahi Kasei Fibers Corp. (AKFC; Osaka, Japan) will collaborate on a new colored nanoparticle designed to increase sensitivity in rapid assays. The new partnership will be based around AKFC's patented high-performance cellulose nanobead product, NanoAct. NanoAct represents a major step forward in visual labels for use in lateral flow and other rapid assays.

Utilizing cellulose technology matured and advanced for more than 80 years, Asahi Kasei developed patented and innovative colored nanobeads, NanoAct. Using the multicolored nanobeads as labels for lateral flow immunoassays, increased sensitivity, and faster test time is expected. NanoAct also has dispersion stability and does not require surfactants for aggregation control.

Consisting of a range of high intensity colored beads NanoAct can be multiplexed, generate higher sensitivity, lower CV's, and improved stability over many existing visual labels such as colloidal gold. This enables the application of lateral flow assays in demanding field assays for emerging infectious disease, consumer applications, biothreat detection, and biomarker testing.

DCN is a supplier of assay development, training, and consulting services to lateral flow assay developers and manufacturers. The company will be AKFC's distribution partner in North America and will be their preferred provider of Original Equipment Manufacturer (OEM) services to NanoAct users worldwide, except Japan.

"This new product line is a great addition to DCN's existing portfolio of high performance reagents and materials for lateral flow test producers," said DCN's president, Brendan O'Farrell. "This new product line is a great addition to DCN's existing portfolio of high performance reagents and materials for lateral flow test producers."

DCN and AKFC will be showcasing NanoAct at the AACC conference in Houston, Texas (USA), on July 28–August 1, 2013.

Related Links:

DCN Diagnostics
Asahi Kasei Fibers Corp.



New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
Auto-Chemistry Analyzer
CS-1200
New
Newborn Screening Test
NeoMass AAAC 3.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.